FUJIFILM Holdings Corporation
FUJIF
Other OTC23.50
USD
- -
- -
CIK
0000800365
ISIN
JP3814000000
Return %
Stock
S&P500
1Y
10.69
17.85
3Y
19.47
64.56
5Y
-7.22
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Teiichi Goto
- Full Time Employees
- 73,526
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 7-3, Akasaka 9-chome Tokyo TY Japan 107-0052
- IPO Date
- Oct 17, 2006
- CIK
- 0000800365
- Website
- holdings.fujifilm.com
- Similar Companies
- Business
- FUJIFILM Holdings Corporation FUJIFILM Holdings Corporation engages in the development, manufacture, and sale of products and services across healthcare, electronics, business innovation, and imaging segments. The company provides healthcare solutions including medical imaging systems, bio-CDMO services for biologics manufacturing, and life science solutions such as cell culture media and regenerative medicine; electronics materials encompassing semiconductor materials, display materials like optical films for flat-panel displays, and other advanced materials; business innovation offerings comprising business and office solutions including document management and photocopiers, as well as graphic communications equipment and materials; and imaging products such as consumer cameras including Instax instant cameras, professional imaging equipment, photographic films, and lenses. Founded in 1934 and headquartered in Tokyo, Japan, FUJIFILM Holdings Corporation operates globally with consolidated subsidiaries in over 270 companies across regions including North America, Europe, Asia-Pacific, and ASEAN countries, targeting healthcare providers, electronics manufacturers, enterprises, and consumers. Recent developments include the completion of a new advanced semiconductor materials building in Shizuoka in November 2025, the launch of joint research with Japan's National Cancer Center in November 2025 to advance cancer treatments, the planned opening of NURA health screening centers in Vietnam, Thailand, the Philippines, and Malaysia in October 2025, and the May 2023 acquisition of Entegris's semiconductor high-purity process chemicals business for $700 million to strengthen its electronics materials portfolio.